Abbott's MDx Sales Rise 14 Percent in Q1 | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Abbott today reported that its molecular diagnostics sales for the first quarter of 2011 grew around 14 percent year over year.

The Abbott Park, Ill.-based maker of medical diagnostics and devices, pharmaceuticals, and nutritional products, said that its molecular diagnostics products brought in revenue of $99 million for the quarter. Of that total, $45 million came from the US market and the rest from international markets.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: experts say race is not a sufficient proxy for studying human genetic diversity and more.

Technology Review writes that CRISPR/Cas9 gene editing firm Editas' success may hinge on a patent case.

Researchers unearthed a bioinformatics error in the Science paper reporting the first ancient African genome, and the authors are seeking an erratum.

A boy's cystic fibrosis carrier status was revealed by a teacher to the parents of children with CF who then sought the boy's transfer to another school, leading to a lawsuit.